soluble T-cell receptor therapy targeting KRas (Zelluna Immunotherapy)

N/A

Report date: 2025/03/20 09:18:56

Base Information

Drug Namesoluble T-cell receptor therapy targeting KRas (Zelluna Immunotherapy)
Drug Alias NamesTCR therapy targeting KRas (Zelluna Immunotherapy)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZelluna Immunotherapy AS
China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A